Erin Talbert, PhD

Contact Information 

Office: 1269B CBRB 
Phone: 467-4667
Faculty Profile

Brief description of current research: 

The Talbert lab is interested in how skeletal muscle is lost in people and animals with disease. Because muscle wasting in cancer patients is associated with poor outcomes, we’re particularly interested in how and why people and animals with cancer lose skeletal muscle mass and ways in which these losses can be prevented. We have a particular interest in how pancreatic cancer causes muscle loss, as pancreatic cancer patients have the highest incidence and severity of muscle wasting. Muscle wasting in pancreatic cancer patients is commonly associated with diabetes, and in particular, new-onset diabetes, and I’m interested in exploring this relationship.

3 most influential diabetes/obesity/metabolism publications:

  • Talbert EE, Cuitiño MC, Ladner KJ, Rajasekera PV, Siebert M, Shakya R, Leone GW, Ostrowski MC, Paleo B, Weisleder N, Reiser PJ, Webb A, Timmers CD, Eiferman DS, Evans DC, Dillhoff ME, Schmidt CR, Guttridge DC. “Modeling Human Cancer-induced Cachexia”. Cell Rep. 6;28(6):1612-1622 (2019).
  • Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, Haverick E, Sarna A, Bloomston M, Pawlik TM, Zimmers TA, Lesinski GB, Hart PA, Dillhoff ME, Schmidt CR, Guttridge DC. “Circulating MCP-1 is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer Patients”. J Cachexia Sarcopenia Muscle. 9(2):358-368 (2018).
  • Talbert EE*, Yang J*, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, and Lesinski GB. “Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through Both Tumor Extrinsic and Intrinsic Activities” Mol Cancer Ther 16(2):344-356 (2017).


"I’m passionate about how skeletal muscle mass allows people to maintain active, healthy lives and about understanding why certain pathologies"